Mo2 - Modelling Overall Survival in Immunotherapy Using Parametric Techniques: Avelumab in Previously Treated Metastatic Merkel Cell Carcinoma

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.062
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Updated Efficacy of Avelumab in Patients With Previously Treated Metastatic Merkel Cell Carcinoma After ≥1 Year of Follow-Up: JAVELIN Merkel 200, a Phase 2 Clinical Trial

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2018English

PD-L1 Inhibition With Avelumab for Metastatic Merkel Cell Carcinoma

Expert Review of Clinical Pharmacology
MedicineToxicologyPharmaceuticsPharmacology
2018English

Efficacy and Safety of First-Line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma

JAMA Oncology
Cancer ResearchOncology
2018English

Minimal Impact on Patients’ Health Utilities Associated With Adverse Events in Metastatic Merkel Cell Carcinoma Patients on Treatment With Avelumab

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab

Frontiers in Oncology
Cancer ResearchOncology
2019English

Predictors of Progression-Free Survival and Overall Survival in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Single-Center Experience

World Journal of Oncology
Cancer ResearchOncology
2019English

Impact of Comorbidity on Overall Survival in Patients Surgically Treated for Renal Cell Carcinoma

Urology
Urology
2008English

Avelumab in the Treatment of Patients With Merkel Cell Carcinoma: Initial Results of Early Access Program in Russia

Malignant tumours
2019English

Case Report: Metastatic Esophageal Squamous Cell Carcinoma Successfully Treated With Immunotherapy: First Case Report in Thailand.

The Bangkok Medical Journal
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy